How Is the Conversation around Space Sustainability Evolving?

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

 

Space to Grow closed out its first season with a wrap-up episode with hosts Chris Blackerby and Charity Weeden from Astroscale. They looked back on past conversations regarding space sustainability, policy, technology, and more. Then shared what they hope to bring to the show in its second season.

“The best part has been the guests we’ve had and the diversity of those voices,” Weeden said. Blackerby echoed this sentiment, highlighting the nine space experts who were on the show.

“The space community recognizes the importance, but most people outside of it don’t know how space affects them because it’s hard to grasp. Our speakers explained how orbital environments and space impact society.” – Chris Blackerby

Weeden noted a central theme in their messages on achieving sustainability. “It’s time to change our culture and how we view space to make it more sustainable.”

Blackerby also remarked about how their conversations have created awareness of the impact on society. “The space community recognizes the importance, but most people outside of it don’t know how space affects them because it’s hard to grasp. Our speakers explained how orbital environments and space impact society.”

While they covered many topics, Weeden said, “We could’ve been more technology focused and explaining how the technology works. Space sustainability is a multi-disciplinary issue.”

Blackerby agreed they should prioritize technical topics. He also wants to dig in more on the fundraising, customer development, investments, and business side of space. “There are more stories about the growth of companies, big and small, and how they form and grow to tell.”

Ultimately, the resounding emphasis of the show is promoting the responsible use of space and moving to a “leave no trace” culture.

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More